Innovo Mimetics
Chick Egg Assay System for Cancer Therapies
Company Overview
Snapshot
Founded in March 2010 by Jonathan Goldstein, Innovo Mimetics operates with 1–10 employees. The company has secured $160K in total capital raised across four funding rounds. Innovo Mimetics ceased operations in December 2024.
Business overview
Innovo Mimetics specializes in anti-cancer therapy efficacy assays, utilizing its proprietary ScreenOvo system. This technology leverages the chick egg tumor xenograft model to evaluate chemical, biological, and cell therapies rapidly and cost-effectively. ScreenOvo is designed as a service tool for immunotherapy and pharmaceutical companies, providing data on cancer cell recognition, killing, tumor infiltration, antibody-dependent cellular cytotoxicity, and checkpoint inhibition, serving the oncology, pharmaceuticals, and drug discovery sectors in Europe, Israel, and the United States.
Log in to access full profile ›Company Intelligence Q&A
- What is Innovo Mimetics' primary focus?
- Innovo Mimetics specializes in developing anti-cancer therapy efficacy assays using its proprietary ScreenOvo system, which is based on the chick egg tumor xenograft model.
- When was Innovo Mimetics founded?
- Innovo Mimetics was founded in March 2010.
- Who founded Innovo Mimetics?
- Innovo Mimetics was founded by Jonathan Goldstein.
- What is the status of Innovo Mimetics?
- Innovo Mimetics is non-active and ceased to operate in December 2024.
- What is ScreenOvo?
- ScreenOvo is Innovo Mimetics' proprietary assay system that allows for rapid and low-cost evaluation of chemical, biological, and cell therapies in a living tumor model, providing data for cancer therapy pipelines and drug discovery.